Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG and keeping the price target at CHF160.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that highlight Galderma Group AG’s promising growth potential. The company’s management has demonstrated confidence in achieving mid-term growth ambitions, which is supported by the current dynamics within the Injectable Aesthetics market. This sector is showing robust growth, and Galderma’s strategic positioning within it is a key driver of their positive outlook.
Additionally, the ongoing launch of Nemluvio, a treatment for atopic dermatitis and prurigo nodularis, is expected to bolster the company’s revenue streams. The successful rollout of this product could significantly enhance Galderma’s market presence and financial performance. These elements collectively underpin the Buy rating, reflecting optimism about the company’s future prospects and strategic initiatives.
Jackson CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Novo Nordisk, and Roche Holding AG. According to TipRanks, Jackson CFA has an average return of 5.6% and a 58.33% success rate on recommended stocks.
In another report released yesterday, Barclays also reiterated a Buy rating on the stock with a CHF155.00 price target.